Vaccines MDPI

We are happy to invite you to the 2nd International Electronic Conference on Vaccines hosted by Vaccines MDPI on November 27-29, 2024. Chaired by Professor Louise Cosby from the School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast in UK, and the Agri-Food and Biosciences Institute in UK. Her research has focused on the elucidation of pathogenic mechanisms of the measles virus, the closely related veterinary morbilliviruses and more recently bovine respiratory syncytial, herpes and coronaviruses. The abstract submission deadline is on the 16th of August and we have prepared 6 awards for the Best Oral Presentation and the Best Poster. We hope to receive your registration and submissions soon! You can find more info at: https://lnkd.in/gc3cRa36

🚨 New Research Alert! 🚨 I am very excited to announce that our research team has just published a new paper on Vaccines MDPI! @MDPIOpenAccess 🎉 Our study dives deep into how cancer patients respond to COVID-19 vaccine booster doses. Given the higher risk these patients face when contracting SARS-CoV-2, understanding their immune response to vaccination is critical. The study analyzed 284 cancer patients from the Portuguese Oncology Institute of Porto (IPO-Porto) and 140 healthy individuals, measuring antibody responses over time. 💡 Our results underscore the importance of tailored vaccination strategies to better protect this vulnerable population. Thank you to everyone involved in making this research possible! Instituto Português de Oncologia do Porto (IPO-Porto) #ciipop #ipoporto #CancerResearch #COVID19 #COVIDBooster #Vaccines #Immunology #Oncology #Healthcare #PublicHealth

Very pleased to present my research titled "Regulating the use of AI in mRNA vaccine development through policy coherence" in the upcoming 2nd International Electronic Conference on Vaccines, Part of the International Electronic Conference on Vaccines series, from 27 to 29 November 2024 (organized by Vaccines MDPI, Web of Science SCIE). 👉 Abstract: Artificial intelligence (AI) has become a game-changer in advancing mRNA vaccine development, bringing unparalleled speed and efficiency to research. AI-driven tools play a crucial role in enhancing vaccine potency and stability by optimizing gene sequences. This results in vaccines that provoke stronger immune responses and are more resistant to degradation. Such progress could enhance health equity and global vaccine distribution, especially in areas lacking adequate cold storage facilities. However, integrating AI into vaccine development poses several technical, ethical and regulatory challenges. One significant hurdle is accurately identifying antigens that can trigger effective immune responses. Additionally, the swift pace of AI-driven research often surpasses current regulatory frameworks, necessitating a delicate balance between innovation and oversight. Ethical issues such as data privacy, algorithmic bias, safety, explainability and transparency in decision-making processes must be tackled to maintain public trust. Regulatory agencies are addressing these obstacles by formulating guidelines covering data authenticity, reliability, transparency, and real-world patient monitoring. A risk-based AI regulation approach is being explored, requiring robust governance structures and collaborative efforts among global regulatory bodies. While AI shows great potential in transforming mRNA vaccine development, concerted efforts are crucial to navigate challenges and ensure the safe and equitable realization of its benefits worldwide. #AI #ethics #explainability #transparency #vaccines #mRNA #healthcare #health #accesstohealth #publichealth #UNSDGs #globalhealth #IECV2024 #healthequity #policycoherence   https://lnkd.in/dgD-jQcy

We are excited to announce the opening of submissions for our latest Special Issue: "Cost-Effectiveness of Vaccines and Public Health," under the leadership of Dr. Sachin A. Silva (Harvard T.H. Chan School of Public Health). Research topics: - #CostEffectiveness - #PublicHealthValue - #vaccines - #valuation - #vaccination - #immunization - #BenefitCost - #welfare - #ExtendedCostEffectiveness - #QALYs Please be aware that the deadline for manuscript submissions is November 30, 2025. For further details, please visit: https://lnkd.in/gCqujbd6

We are thrilled to announce the launch of our new Special Issue now open for submissions: "Vaccine Against Sexually Transmitted Diseases," led by Dr. Weiming Tang. This Special Issue emphasizes the importance of preventive measures, equitable access to vaccines, and the integration of vaccination programs into public health initiatives. By showcasing interdisciplinary collaborations and emerging technologies, this Special Issue aims to foster dialogue among researchers, clinicians, and policymakers to enhance global health outcomes and reduce the burden of STIs. Please note that the deadline for manuscript submissions is 30 September 2025. For more information, visit: https://lnkd.in/gDjdtz2j #vaccination #SexuallyTransmittedInfections; #HPV; #HIV; #syphilis, #gonorrhea, and #chlamydia; #VaccineDevelopment; #PublicHealth; #epidemiology; #HealthEquity; #PreventiveStrategies

#Award The deadline for applications for the /Vaccines Travel Award/ is fast approaching! Be sure to submit your applications online by *01 November 2024*. **Eligibility and Requirements** – Postdoctoral fellows or PhD students – Plans to attend an international conference in 2025 (oral presentation or poster) **List of Documents for Application** – Information about the conference the applicant is planning to attend and the abstract that will be submitted – Curriculum Vitae and list of publications – Justification letter describing the focus of the research (max. 800 words) – Letter of recommendation from the supervisor, research director, or department head, which also confirms the applicant’s status as a postdoctoral fellow/PhD student. For more information and to apply, visit: https://lnkd.in/egCcrD6G #vaccines #TravelAward

We are excited to announce the launch of a new Special Issue now open for submissions: "Personalised Cancer Vaccines", led by Dr. Andrew Coveler. In this Special Issue, novel cancer vaccines, adjuvants, and therapeutics will be examined, with regard to their regulation and treatment of disease. Cancer vaccines are coming. 📆The deadline for manuscript submissions is April 30, 2025. 💡For further details, please visit: https://lnkd.in/gNjhwi5Z #PeptideVaccines #mRNAvaccines #DNAvaccines #CancerVaccines

We are excited to announce a new Special Issue now open for submissions: "Immune Responses in Patients with Inflammatory Bowel Disease after Vaccination"! We are honored to have Dr. Phil-Robin Tepasse and Dr. Arne Bokemeyer as our guest editors. This Special Issue aims to gather important insights into the immune response to vaccination in patients with inflammatory bowel disease. Both original research articles and reviews are welcome. Research areas may include (but not limited to) basic scientific findings on vaccination from the fields of virology, bacteriology and immunology, innovative approaches to vaccine development and clinical studies on vaccine response and disease progression in IBD patients. Of particular interest are the approaches to prevent opportunistic infections such as cytomegalovirus reactivation. Manuscript submission deadline: 30 June 2025 For further details, please visit: https://lnkd.in/eJjaKaYX #InflammatoryBowelDisease #Vaccination #OpportunisticInfections #ImmuneResponse #ImmunomodulatoryTherapy

We are thrilled to announce the opening of submissions for our new Special Issue: "Monkeypox Vaccine Development and Vaccination Strategies". This issue is guest-edited by Dr. Natalie Prow and Dr. Preethi Eldi. We invite you to submit your research related to scientific advances in the field of monkeypox vaccine development and vaccination strategies. The deadline for manuscript submissions is May 31, 2025. For more information, please visit: https://lnkd.in/eHhqVUfT #MonkeypoxVirus #VaccineDevelopment #VaccinationStrategies

We're excited to share insights from a highly cited paper titled "The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID” This research was one of the first studies to investigate the effects of COVID-19 vaccination on people that were already suffering from Long Covid. Before this research, there was considerable concern in the Long Covid community that vaccination might worsen symptoms. The research found that 82.1% of those surveyed had either improved or unchanged symptoms following vaccination. This suggested that COVID-19 vaccines were safe for the majority of Long Covid patients, though the effect was variable and some degree of caution warranted. Access the full paper: https://lnkd.in/eR3Pzmfh #longCOVID; #vaccination; #survey